Clover Biopharmaceuticals, Ltd. (2197.HK)
HKD 0.26
(0.0%)
HKD 0.26
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.83 Billion CNY | -47.15% |
| 2022 | 5.36 Billion CNY | 29.96% |
| 2021 | 4.12 Billion CNY | 90.14% |
| 2020 | 2.17 Billion CNY | 754.31% |
| 2019 | 254.03 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.63 Billion CNY | -7.21% |
| 2024 Q2 | 2.63 Billion CNY | 0.0% |
| 2023 Q4 | 2.83 Billion CNY | 0.0% |
| 2023 FY | 2.83 Billion CNY | -47.15% |
| 2023 Q3 | 2.83 Billion CNY | -7.09% |
| 2023 Q2 | 3.05 Billion CNY | 0.0% |
| 2023 Q1 | 3.05 Billion CNY | -43.12% |
| 2022 Q2 | 5.03 Billion CNY | 0.0% |
| 2022 Q1 | 5.03 Billion CNY | 22.05% |
| 2022 FY | 5.36 Billion CNY | 29.96% |
| 2022 Q4 | 5.36 Billion CNY | 0.0% |
| 2022 Q3 | 5.36 Billion CNY | 6.48% |
| 2021 FY | 4.12 Billion CNY | 90.14% |
| 2021 Q1 | 4.45 Billion CNY | 0.0% |
| 2021 Q3 | 4.12 Billion CNY | 0.0% |
| 2021 Q4 | 4.12 Billion CNY | 0.0% |
| 2020 FY | 2.17 Billion CNY | 754.31% |
| 2019 FY | 254.03 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -1754.668% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 59.844% |